ArticleJournal of clinical microbiology2026
Mucorales PCR for the rapid diagnosis of mucormycosis: 6 years of testing in a national reference laboratory and tertiary hospital.
Article in Journal of clinical microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mucormycosis is an invasive mold disease (IMD) caused by fungi in the order Mucorales. Early initiation of active antifungal therapy is critical for optimal outcomes, and molecular diagnostics can speed up the time to critical results. We reviewed 6 years of Mucorales polymerase chain reaction (PCR) testing to assess agreement with culture, histopathology, and/or pan-fungal sequencing across different specimen types. Medical record review was also performed to adjudicate cases of suspected IMD from our institution. A total of 5,779 PCRs and 2,017 fungal cultures from the same patients were performed during the study period. PCR results were issued approximately 7 days sooner than Mucorales-positive cultures. The overall PCR positivity rate was 2.9%. Sinus and other fresh tissue specimens had the highest diagnostic yield (23.8% and 19.4% PCR positive, respectively). PCR cycle thresholds (Cts) were significantly earlier for culture-positive specimens and for tissue versus other sample types, while serum had the latest Cts (all comparisons IMPORTANCE: This work addresses a critical gap in the diagnosis of mucormycosis, a rapidly progressive and frequently fatal invasive mold disease for which timely, accurate laboratory confirmation is essential but often difficult to achieve. By evaluating over 6 years of real-world Mucorales polymerase chain reaction (PCR) testing in a national reference laboratory and tertiary-care setting, this study provides robust evidence that targeted PCR offers substantially faster turnaround times than culture while maintaining high specificity across multiple specimen types. The findings underscore the diagnostic value of molecular testing, particularly from fresh tissue obtained at the site of infection, and highlight important limitations of serum testing that can inform optimal test utilization. In the context of increasing mucormycosis incidence, absence of reliable antigen-based diagnostics, and the need for early antifungal therapy, these data support the incorporation of Mucorales PCR as a complementary tool to conventional methods.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.